Neutralization of HIV by milk expressed antibody

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 1, 2013, Pages 10-16

  Yu, Xiaocong ^a,b   Pollock, Daniel ^c   Duval, Mark ^a   Lewis, Christopher ^a   Joseph, Kristin ^c   Meade, Harry ^c   Cavacini, Lisa ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GTC Biotherapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CASEIN; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN A2 ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIRTH; BREAST MILK; BREAST MILK EXPRESSION; CELL KILLING; CHO CELL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE VECTOR; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IC 50; IMMUNOREACTIVITY; MAMMARY GLAND; MEDIATOR; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; TRANSGENIC MOUSE; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; GENE EXPRESSION; HIV; HIV ANTIBODIES; HUMANS; IMMUNOGLOBULIN A; MICE; MICE, TRANSGENIC; MILK; NEUTRALIZATION TESTS; PLASMIDS;

EID: 84871844769     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318271c450     Document Type: Article

References (34)

1. Becquart P, Hocini H, Garin B, et al. Compartmentalization of the IgG immune response to HIV-1 in breast milk. AIDS. 1999;13:1323-1331.
2. Duprat C, Mohammed Z, Datta P, et al. Human immunodeficiency virus type 1 IgA antibody in breast milk and serum. Pediatr Infect Dis J. 1994; 13:603-608.
3. Becquart P, Hocini H, Levy M, et al. Secretory anti-human immunodeficiency virus (HIV) antibodies in colostrum and breast milk are not a major determinant of the protection of early postnatal transmission of HIV. J Infect Dis. 2000;181:532-539.
4. Van de Perre P, Simonon A, Hitimana DG, et al. Infective and antiinfective properties of breastmilk from HIV-1-infected women. Lancet. 1993;341:914-918.
5. Mantis NJ, Palaia J, Hessell AJ, et al. Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region. J Immunol. 2007;179:3144-3152.
6. Roben P, Moore JP, Thali M, et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol. 1994;68:4821-4828.
7. Duval M, Posner MR, Cavacini LA. A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils. J Virol. 2008;82:4671-4674.
8. Wei X, Decker J, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46:1896-1905.
9. Miranda L, Duval M, Doherty H, et al. The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain. J Immunol. 2007;178:7132-7138.
10. Huang MT, Gorman CM. Intervening sequences increase efficiency of RNA 3' processing and accumulation of cytoplasmic RNA. Nucleic Acids Res. 1990;18:937-947.
11. Krugmann S, Pleass RJ, Atkin JD, et al. Structural requirements for assembly of dimeric IgA probed by site-directed mutagenesis of J chain and a cysteine residue of the alpha-chain CH2 domain. J Immunol. 1997; 159:244-249.
12. Sorensen V, Rasmussen IB, Sundvold V, et al. Structural requirements for incorporation of J chain into human IgM and IgA. Int Immunol. 2000; 12:19-27.
13. Forthal D, Gilbert P, Landucci G, et al. Recombinant gp120 vaccineinduced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol. 2007;178:6596-6603.
14. Mascola JR, Louder MK, VanCott TC, et al. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J Virol. 1997;71:7198-7206.
15. Mascola J, Lewis M, Stiegler G, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89. 6PD by passive transfer of neutralizing antibodies. J Virol. 1999;73:4009-40018.
16. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000;6:207-210.
17. Ferrantelli F, Hofmann-Lehmann R, Rasmussen R, et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89. 6P infection or disease in neonatal macaques. AIDS. 2003;17:201-209.
18. Baba T, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simianhuman immunodeficiency virus infection. Nat Med. 2000;6:200-206.
19. Ferrantelli F, Rasmussen R, Buckley K, et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simianhuman immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis. 2004;189:2167-2173.
20. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, et al. Postnatal pre-and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. J Med Primatol. 2002;31:109-119.
21. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol. 2001;75:7470-7480.
22. Hofmann-Lehmann R, Rasmussen RA, Vlasak J, et al. Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant transmission? J Med Primatol. 2001;30:190-196.
23. Pilgrim A, Pantaleo G, Cohen O, et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and longterm-nonprogressive infection. J Infect Dis. 1997;176:924-932.
24. Zhou JY, Montefiori DC. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells. J Virol. 1997;71:2512-2517.
25. Bailey J, Lassen K, Yang H-C, et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active anti-retroviral therapy. J Virol. 2006;80:4758-4770.
26. Woof JM, Russell MW. Structure and function relationships in IgA. Mucosal Immunol. 2011;4:590-597.
27. Biesbrock AR, Reddy MS, Levine MJ. Interaction of a salivary mucinsecretory immunoglobulin A complex with mucosal pathogens. Infect Immun. 1991;59:3492-3497.
28. Magnusson KE, Stjernstrom I. Mucosal barrier mechanisms. Interplay between secretory IgA (SIgA), IgG and mucins on the surface properties and association of salmonellae with intestine and granulocytes. Immunology. 1982;45:239-248.
29. Stubbe H, Berdoz J, Kraehenbuhl J-P, et al. Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile toxin A damaging of T84 monolayers. J Immunol. 2000;164:1952-1960.
30. Walsh E, Falsey A. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis. 2004; 190:373-378.
31. Rocha-Zavaleta L, Barrios T, Garcia-Carranca A, et al. Cervical secretory immunoglobulin A to human papillomavirus type 16 (HPV-16) from HPV-16 infected women inhibit HPV16 virus-like particle-induced hemagglutination of mouse red blood cells. FEMS Immunol Med Microbiol. 2001;31:47-51.
32. Feng N, Lawton J, Gilbert J, et al. Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb. J Clin Invest. 2002; 109:1203-1213.
33. Mofenson LM. Prevention of mother-to-child HIV-1 transmission-why we still need a preventive HIV immunization strategy. J Acquir Immune Defic Syndr. 2011;58:359-362.
34. Onyango-Makumbi C, Omer SB, Mubiru M, et al. Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr. 2011; 58:399-407.